Search

Background The use of antracycline in breast cancer has been associated with adverse cardiac events and its prevention remains an important challenge in cancer. The aim of this study was to evaluate the efficacy of bisoprolol in preventing acute cardiac events caused by anthracycline drugs in breast cancer patients. Methods 70 consecutive breast cancer patients planned to receive anthracycline chemotherapy were enrolled in this double blind, randomized clinical trial. Patients randomly assigned to receive either bisoprolol (2.5 mg daily) or placebo starting from day before chemotherapy up to 14 days after completion of chemotherapy course. One day before the start of chemotherapy and 14 days after the last chemotherapy, the level of Pro-BNP and troponin, CPK, CK-MB and EF (based on MUGA scan) were measured and changes were compared between the two groups. Results There was no significant difference in the level of EF (P = 0.160), CPK (P = 0.295), CK-MB (P = 0.073) or Pro-BNP (P = 0.066) in the bisoprolol group, but a significant decrease was observed in EF in the control group (P = 0.015). There was a significant increase in CPK and Pro-BNP (P = 0.03l; P = 0.048); however, no statistically significant difference in CK-MB was observed (P = 0.710) in the control group. troponin levels were not increased in any patients. Conclusions Our results showed that bisoprolol may have an appropriate preventive effect on the acute complications of anthracycline drugs in patients with breast cancer, thus its use can be recommended to reduce cardiac complications in this group of patients. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]